Expert Commentary Professor Yuan Zhongyu Department of Internal Medicine, Sun Yat-sen University Cancer Prevention and Treatment Center Chief Physician, MD, Doctoral Supervisor Engaged in clinical and research work on breast cancer for many years, has presided over and participated in over 20 clinical studies, involved in several research projects such as the National 863 Program … Read more
Antibody-drug conjugates (ADC) are a novel type of medication that couples monoclonal antibodies, which specifically recognize cancer cell surface antigens, with cytotoxic chemotherapy drugs through specific linkers, exerting a significant tumor-killing effect. Currently, 15 ADC drugs, represented by trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd, DS-8201), have been approved globally, significantly changing the treatment landscape … Read more
iNature Sonochemotherapy (SCT) triggers an excessive production of reactive oxygen species (ROS) and controlled release of chemotherapeutic drugs through ultrasound, becoming a powerful cancer treatment method. However, achieving spatiotemporal controlled release of chemotherapeutic drugs during ROS generation remains a significant challenge. On December 17, 2024, a collaborative research paper titled“Cascade-Activatable Nanoprodrug System Augments Sonochemotherapy of … Read more
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer after hepatocellular carcinoma, accounting for approximately 10%-15% of primary liver cancer cases, and is rightly termed the “second-in-command” killer within the liver. Over the past 40 years, the incidence of ICC has been on the rise globally, particularly pronounced in Asia. ▲ Image source: … Read more